Salivary gland cancer: ESMO–European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up
C. van Herpen, Vincent Vander Poorten, Alena Skálová, Chris H.J. Terhaard, Roberto Maroldi, A. van Engen, B. Baujat, Laura D. Locati, Alexandra Jensen, Ludi E. Smeele, José A. Hardillo, Valérie Costes Martineau, Annalisa Trama, E. Kinloch, C. Even, Jean-Pascal Machiels
Abstract
Major salivary gland cancers (SGCs) comprise 5% of head and neck cancers in Europe. The worldwide crude and age-adjusted incidence rates are 0.69 and 0.57 cases per 100 000 people per year, respectively, with 53 583 new patients in 2020. In Europe, crude and age-adjusted incidence rates are 1.3 and 0.67 cases per 100 000 people per year, respectively, with 9917 new patients in 2020.1 Data for minor SGCs are limited, but the RARECARENet project estimated the crude incidence of minor salivary gland-type cancers of the head and neck to be 0.4 cases per 100 000 people in the 2000-2007 diagnosis period; minor SGCs have a slight predominance in males and incidence is highest in the elderly (>65 years).